PRNewsWire<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies, Inc. (Optieum), a preclinical stage company dedicated to the discovery and development of innovative CAR-T cell therapies,\u00a0 announced a partnership for cGMP manufacturing of the lentiviral vector (LVV) construct used in the production of OPTF01, a novel CAR-T therapy for glioblastoma treatment. Derived from Optieum’s proprietary Eumbody System, OPTF01 specifically targets Fibroblast activation protein-alpha (FAP\u03b1), a protein expressed on both tumor cells and the surrounding pericytes and Cancer-associated Fibroblasts (CAFs). Hence, OPTF01 can potentially disrupt the immunosuppressive microenvironment around the tumor while simultaneously attacking the malignant cells within the tumor. Successful development of this therapeutic approach […]<\/p>\n","protected":false},"author":4,"featured_media":11109,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,181,89,211,237,206],"tags":[150,3885,3886,3888,3884,3887],"ppma_author":[205],"class_list":{"0":"post-11108","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-apac","8":"category-biotech","9":"category-health-tech","10":"category-japan","11":"category-news","12":"category-regional","13":"tag-biotech","14":"tag-car-t-therapy","15":"tag-cgmp-manufacturing","16":"tag-genezen","17":"tag-glioblastoma","18":"tag-optieum-biotechnologies"},"yoast_head":"\n
Genezen, Optieum Partner on CAR-T Therapy Manufacturing<\/title>\n<meta name=\"description\" content=\"Genezen and Optieum partner for cGMP manufacturing of the lentiviral vector in OPTF01, a novel CAR-T therapy for glioblastoma treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genezen, Optieum Partner on CAR-T Therapy Manufacturing\" \/>\n<meta property=\"og:description\" content=\"Genezen and Optieum partner for cGMP manufacturing of the lentiviral vector in OPTF01, a novel CAR-T therapy for glioblastoma treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-06T13:20:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/05\/Genezen-and-Optieum-Biotechnologies-Partner-to-Support-cGMP-Manufacturing-of-Groundbreaking-CAR-T-Therapy-for-Glioblastoma.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genezen\u793e\u3068Optieum\u793e\u304cCAR-T\u7642\u6cd5\u88fd\u9020\u3067\u63d0\u643a","description":"Genezen\u793e\u3068Optieum\u793e\u3001\u795e\u7d4c\u81a0\u82bd\u816b\u6cbb\u7642\u7528\u306e\u65b0\u898fCAR-T\u7642\u6cd5\u3067\u3042\u308bOPTF01\u306e\u30ec\u30f3\u30c1\u30a6\u30a4\u30eb\u30b9\u30d9\u30af\u30bf\u30fc\u306ecGMP\u88fd\u9020\u306b\u3064\u3044\u3066\u63d0\u643a\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/","og_locale":"ja_JP","og_type":"article","og_title":"Genezen, Optieum Partner on CAR-T Therapy Manufacturing","og_description":"Genezen and Optieum partner for cGMP manufacturing of the lentiviral vector in OPTF01, a novel CAR-T therapy for glioblastoma treatment.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/","og_site_name":"itbusinesstoday","article_published_time":"2025-05-06T13:20:29+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/05\/Genezen-and-Optieum-Biotechnologies-Partner-to-Support-cGMP-Manufacturing-of-Groundbreaking-CAR-T-Therapy-for-Glioblastoma.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Genezen, Optieum Partner to Support cGMP Manufacturing","datePublished":"2025-05-06T13:20:29+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/"},"wordCount":368,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/05\/Genezen-and-Optieum-Biotechnologies-Partner-to-Support-cGMP-Manufacturing-of-Groundbreaking-CAR-T-Therapy-for-Glioblastoma.webp","keywords":["Biotech","CAR-T Therapy","cGMP Manufacturing","Genezen","Glioblastoma","Optieum Biotechnologies"],"articleSection":["APAC","Biotech","Health Tech","Japan","News","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/","name":"Genezen\u793e\u3068Optieum\u793e\u304cCAR-T\u7642\u6cd5\u88fd\u9020\u3067\u63d0\u643a","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/05\/Genezen-and-Optieum-Biotechnologies-Partner-to-Support-cGMP-Manufacturing-of-Groundbreaking-CAR-T-Therapy-for-Glioblastoma.webp","datePublished":"2025-05-06T13:20:29+00:00","description":"Genezen\u793e\u3068Optieum\u793e\u3001\u795e\u7d4c\u81a0\u82bd\u816b\u6cbb\u7642\u7528\u306e\u65b0\u898fCAR-T\u7642\u6cd5\u3067\u3042\u308bOPTF01\u306e\u30ec\u30f3\u30c1\u30a6\u30a4\u30eb\u30b9\u30d9\u30af\u30bf\u30fc\u306ecGMP\u88fd\u9020\u306b\u3064\u3044\u3066\u63d0\u643a\u3002.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/05\/Genezen-and-Optieum-Biotechnologies-Partner-to-Support-cGMP-Manufacturing-of-Groundbreaking-CAR-T-Therapy-for-Glioblastoma.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/05\/Genezen-and-Optieum-Biotechnologies-Partner-to-Support-cGMP-Manufacturing-of-Groundbreaking-CAR-T-Therapy-for-Glioblastoma.webp","width":1200,"height":800,"caption":"Genezen"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/genezen-optieum-partner-to-support-cgmp-manufacturing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Genezen, Optieum Partner to Support cGMP Manufacturing"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/11108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=11108"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/11108\/revisions"}],"predecessor-version":[{"id":11110,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/11108\/revisions\/11110"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/11109"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=11108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=11108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=11108"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=11108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}